Quarterly report pursuant to Section 13 or 15(d)

NON CONTROLLING INTEREST (Tables)

v3.24.1.1.u2
NON CONTROLLING INTEREST (Tables)
3 Months Ended
Mar. 31, 2024
NON CONTROLLING INTEREST  
Schedule of net loss attributable to non-controlling interest

 

 

BioCorRx

Pharmaceuticals,

Inc.

 

 

Joseph

DeSanto

MD

 

Net loss

 

$ (1,549 )

 

$ (892 )

Average Non-controlling interest percentage of profit/losses

 

 

24.2 %

 

 

35.0 %

Net loss attributable to the non-controlling interest

 

$ (375 )

 

$ (312 )

 

 

BioCorRx

Pharmaceuticals,

Inc.

 

 

Joseph

DeSanto

MD

 

Net loss

 

$ (1,447 )

 

$ (1,668 )

Average Non-controlling interest percentage of profit/losses

 

 

24.2 %

 

 

35.0 %

Net loss attributable to the non-controlling interest

 

$ (350 )

 

$ (584 )
Schedule of changes in non controlling interest

Balance, December 31, 2023

 

$ (128,834 )

Net loss attributable to the non-controlling interest

 

 

(687 )

Balance, March 31, 2024

 

 

(129,521 )

Balance, December 31, 2022

 

$ (125,257 )

Net loss attributable to the non-controlling interest

 

 

(934 )

Balance, March 31, 2023

 

 

(126,191 )